Interní Med. 2011; 13(10): 374-377

Current perspective on diagnosing and treating ankylosing spondylitis

doc.MUDr.Ladislav Šenolt, Ph.D.
Revmatologický ústav, Klinika revmatologie 1. LF UK Praha

Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the axial skeleton that causes inflammatory back pain

and may lead to structural spinal damage, functional handicap and major reduction in the quality of life. The diagnosis of ankylosing

spondylitis is based on the 1984 modified New York criteria that require radiographic evidence of damage to the sacroiliac joints. The

use of magnetic resonance imaging and of modern therapeutic options has substantially improved the approach to this condition. The

author provides an overview of the classification criteria for axial spondyloarthritis and a recently defined guideline on ankylosing

spondylitis including the possibility to use biological therapy in individuals with a severe course of axial spondyloarthritis already in an

early stage of the disease.

Keywords: ankylosing spondylitis, axial spondyloarthritis, sacroileitis, biological therapy

Published: October 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šenolt L. Current perspective on diagnosing and treating ankylosing spondylitis. Interní Med. 2011;13(10):374-377.
Download citation

References

  1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379-1390. Go to original source... Go to PubMed...
  2. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol. 2001; 28: 2283-2288. Go to PubMed...
  3. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005; 64: 659-663. Go to original source... Go to PubMed...
  4. Forejtová S, Mann H, Stolfa J, et al. Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 2008; 27: 1005-1013. Go to original source... Go to PubMed...
  5. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-783. Go to original source... Go to PubMed...
  6. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70: 896-904. Go to original source... Go to PubMed...
  7. Mielants H, Van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009; 27(Suppl 55): S56-61. Go to PubMed...
  8. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009; 68: 784-788. Go to original source... Go to PubMed...
  9. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27: 361-368. Go to original source... Go to PubMed...
  10. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009; 68: 1520-1527. Go to original source... Go to PubMed...
  11. Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004; 63: 535-543. Go to original source... Go to PubMed...
  12. Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52: 1756-1765. Go to original source... Go to PubMed...
  13. Haibel H, Specker C. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009; 27(Suppl 55): S159-163. Go to PubMed...
  14. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193. Go to original source... Go to PubMed...
  15. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48: 3230-3236. Go to original source... Go to PubMed...
  16. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2006; 54: 2136-2146. Go to original source... Go to PubMed...
  17. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase Ii trial. Arthritis Rheum. 2008; 58: 3402-3412. Go to original source... Go to PubMed...
  18. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006; 65: 442-452. Go to original source... Go to PubMed...
  19. van der Heijde D, Sieper J, Maksymowych WP, et al. for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70: 905-908. Go to original source... Go to PubMed...
  20. Pavelka K, Štolfa J, Vencovský J. Doplněk standardních léčebných postupů u ankylozující spondylitidy. Čes. Revmatol. 2004; 1: 30-35.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.